3 results about "Leukemia cell line" patented technology

This invention relates to the field of pharmaceutical technology, specifically to the application of *Citrus aurantium* in the preparation of antitumor drugs. The invention uses *Citrus aurantium* as a raw material to obtain, for the first time, extracts with antitumor activity and novel compounds with extremely high activity. Furthermore, it provides a new natural method for obtaining *Citrus aurantium* alkaloids A, B, C, and D. The extracts and isolated monomeric compounds can effectively inhibit the growth of various tumor cell lines in vitro, including human colorectal cancer cells, human chronic myeloid leukemia cell lines, human gastric adenocarcinoma cell lines, human small cell lung cancer cell lines, and human liver cancer cell lines. The obtained extracts and monomeric compounds target a wide range of cancer cells, exhibiting significant effects on various cancer cells, thus achieving therapeutic effects and showing broad application prospects.

This useful solution refers to a procedure for isolating and purifying the compound kaempterol-3-O-rhamnoside from the bark of the medicinal tree Schima wallichii (DC.) Korth., which exhibits cytotoxic activity against HL-60 leukemia cells. The process according to the solution includes the following steps: a) preparing the raw material from the bark of the medicinal plant *Euphorbia hirta*; b) extracting the powdered raw material with 70% ethanol to obtain the ethanol extract labeled VT-E; c) dissolving the VT-E extract in hot water to obtain a liquid mixture; d) partition extraction with n-hexane to obtain the n-hexane extract labeled VT-H; e) partition extraction with dichloromethane to obtain the dichloromethane extract labeled VT-DCM; f) partition extraction with ethyl acetate to obtain the ethyl acetate extract labeled VT-EA. g) Isolating the fraction containing kaempferol-3-O-rhamnoside from the VT-EA extract using silica gel column chromatography to obtain the fraction labeled VT-EA-6; h) Purifying the VT-EA-6 fraction using column chromatography to obtain the fraction labeled VT-EA-6-3; i) Purifying the VT-EA-6-3 fraction using silica gel column chromatography to obtain the kaempferol-3-O-rhamnoside compound with formula (1). The compound kaempferol-3-O-rhamnoside obtained by the utility solution procedure exhibited significant cytotoxic activity against HL60 leukemia cell line under in vitro conditions.

The application belongs to the technical field of biological medicine, and particularly relates to application of circular RNA (circRNA) CIRC8341 in leukemia. The application proves that the circular RNA CIRC8341 is stably present in leukemia cells and is generally highly expressed in leukemia cell lines through RNase R experiments and qRT-PCR experiments. Meanwhile, it is found through research that targeting CIRC8341 can significantly inhibit the growth of leukemia cells; the test results of a mouse leukemia model show that knocking down the expression of CIRC8341 can significantly inhibit the survival of leukemia cells and significantly prolong the survival cycle of model mice. The above results show that CIRC8341 can play a role in leukemia as a therapeutic target.